A young asian boy with vitiligo smiles warmly while standing in a sunlit park. he wears a bright yellow shirt, with a playground blurred in the background, diversity and inclusivity.

True-ViP-2

A clinical trial testing how safe and effective ruxolitinib cream is for children aged 6 to 11 with non-segmental vitiligo.

A young asian boy with vitiligo smiles warmly while standing in a sunlit park. he wears a bright yellow shirt, with a playground blurred in the background, diversity and inclusivity.

About True-ViP-2

Vitiligo is a chronic autoimmune skin condition that causes patches of skin to lose their pigment, resulting in areas of lighter skin. Although the condition is not physically harmful, it can have a significant impact on self-esteem, emotional wellbeing, and quality of life, particularly in children and young people. Effective treatment options for younger children remain limited, creating a need for further research into safe and targeted therapies. The TRuE-ViP-2 study is a clinical trial evaluating the safety and efficacy of topical ruxolitinib cream in children with non-segmental vitiligo. Through regular clinical assessments and long-term follow-up, the study aims to determine how effectively ruxolitinib can restore skin pigmentation while monitoring its safety and tolerability in a paediatric population. Findings from the study may help expand treatment options for children with vitiligo and support the development of evidence-based approaches to managing this condition.

Study details

Condition

Vitiligo

Drug

Ruxolitinib

Age range

6-11

Funder

Incyte Corporation